198 results match your criteria: "Cancer Research Center of Toulouse CRCT[Affiliation]"

Background: The Complexity INdex in SARComas (CINSARC) is a transcriptional signature derived from the expression of 67 genes involved in mitosis control and chromosome integrity. This study aims to assess CINSARC value of in an independent series of high-risk patients with localized soft tissue sarcoma (STS) treated with preoperative chemotherapy within a prospective, randomized, phase III study (ISG-STS 1001).

Patients And Methods: Patients with available pre-treatment samples, treated with 3 cycles of either standard (ST) preoperative or histotype-tailored (HT) chemotherapy, were scored according to CINSARC (low-risk, C1; high-risk, C2).

View Article and Find Full Text PDF

The effect of major postoperative complications on recurrence and long-term survival after cytoreductive surgery for ovarian cancer.

Gynecol Oncol

July 2022

Department of Surgical Oncology, Institut Claudius Regaud, Toulouse University Cancer Institute (IUCT) - Oncopole, Toulouse, France; Tumor Immunology and Immunotherapy team 1, Cancer Research Center of Toulouse (CRCT), INSERM, Toulouse, France.

Objective: To assess the impact on survival of major postoperative complications and to identify the factors associated with these complications in patients with advanced ovarian cancer after cytoreductive surgery.

Methods: We designed a retrospective multicenter study collecting data from patients with IIIC-IV FIGO Stage ovarian cancer who had undergone either primary debulking surgery (PDS), early interval debulking surgery (IDS) after 3-4 cycles of neoadjuvant chemotherapy, or delayed debulking surgery (DDS) after 6 cycles, with minimal or no residual disease, from January 2008 to December 2015. Univariable and multivariable analyses were conducted to identify factors associated with major surgical complications (≥Grade 3).

View Article and Find Full Text PDF

Celebrating the 10th anniversary of the creation of the European Network for Oxysterol Research (ENOR).

J Steroid Biochem Mol Biol

July 2022

UOC of Internal Medicine, Sapienza University of Rome, ICOT Hospital, Latina, & Vascular Biology & Mass Spectrometry Laboratory, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. Electronic address:

View Article and Find Full Text PDF

Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours.

Neuropathol Appl Neurobiol

August 2022

APHM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.

Aim: Rosette-forming glioneuronal tumour (RGNT) is a rare central nervous system (CNS) World Health Organization (WHO) grade 1 brain neoplasm. According to the WHO 2021, essential diagnostic criteria are a 'biphasic histomorphology with neurocytic and a glial component, and uniform neurocytes forming rosettes and/or perivascular pseudorosettes associated with synaptophysin expression' and/or DNA methylation profile of RGNT whereas 'FGFR1 mutation with co-occurring PIK3CA and/or NF1 mutation' are desirable criteria.

Material And Methods: We report a series of 46 cases fulfilling the essential pathological diagnostic criteria for RGNT.

View Article and Find Full Text PDF

Background: Glioblastoma is the most frequent malignant primitive brain tumor in adults. The treatment includes surgery, radiotherapy, and chemotherapy. During follow-up, combined chemoradiotherapy can induce treatment-related changes mimicking tumor progression on medical imaging, such as pseudoprogression (PsP).

View Article and Find Full Text PDF

Anti-CD38 monoclonal antibodies (mAbs) represent a breakthrough in the treatment of multiple myeloma (MM), yet some patients fail to respond or progress quickly with this therapy, highlighting the need for novel approaches. In this study we compared the preclinical efficacy of SAR442085, a next-generation anti-CD38 mAb with enhanced affinity for activating Fcγ receptors (FcγR), with first-generation anti-CD38 mAb daratumumab and isatuximab. In surface plasmon resonance and cellular binding assays, we found that SAR442085 had higher binding affinity than daratumumab and isatuximab for FcγRIIa (CD32a) and FcγRIIIa (CD16a).

View Article and Find Full Text PDF

In this study, a radiomics analysis was conducted to provide insights into the differentiation of radionecrosis and tumor progression in multiparametric MRI in the context of a multicentric clinical trial. First, the sensitivity of radiomic features to the unwanted variability caused by different protocol settings was assessed for each modality. Then, the ability of image normalization and ComBat-based harmonization to reduce the scanner-related variability was evaluated.

View Article and Find Full Text PDF

Fabry disease (FD) is an X-linked genetic disease due to pathogenic variants in GLA. The phenotype varies depending on the GLA variant, alpha-galactosidase residual activity, patient's age and gender and, for females, X chromosome inactivation. Over 1000 variants have been identified, many through screening protocols more susceptible to disclose non-pathogenic variants or variants of unknown significance (VUS).

View Article and Find Full Text PDF

Sterol metabolism and cancer.

Biochem Pharmacol

February 2022

Team "Cholesterol Metabolism and Therapeutic Innovations", Cancer Research Center of Toulouse (CRCT), UMR 1037 INSERM, UMR 5071 CNRS, Université de Toulouse III, Toulouse, France; Equipe labellisée par la Ligue Nationale Contre le Cancer, France; French Network for Nutrition And Cancer Research (NACRe Network), France. Electronic address:

View Article and Find Full Text PDF

FDG-PET/CT in Lymphoma: Where Do We Go Now?

Cancers (Basel)

October 2021

Nuclear Medicine Department, Institute Claudius Regaud, 31100 Toulouse, France.

Article Synopsis
  • FDG-PET/CT is crucial in managing lymphoma patients, aiding in staging and evaluating treatment response.
  • Efforts have been made to standardize PET acquisition and reporting, particularly through the use of the 5-point Deauville scale, which helps determine treatment success or failure.
  • The review discusses clinical trial evidence supporting PET-directed treatment personalization in lymphoma and suggests the potential for new PET metrics and radiopharmaceuticals in future applications.
View Article and Find Full Text PDF

Purpose: Patients with locally advanced grade 2-3 extremity/truncal soft tissue sarcomas (STS) are at high risk of recurrence. The objective of this study was to assess the efficacy and feasibility of neoadjuvant concurrent chemoradiotherapy (cCRT) in selected grade 2-3 patients with limb or trunk wall STS, and to compare this schedule to a sequential approach combining neoadjuvant chemotherapy and adjuvant radiotherapy.

Methods: We retrospectively included patients who underwent neoadjuvant cCRT at two comprehensive cancer centers from 1992-2016.

View Article and Find Full Text PDF

In this study, we report the clinical features of Kelch-like protein 11 antibody-associated paraneoplastic neurological syndrome, design and validate a clinical score to facilitate the identification of patients that should be tested for Kelch-like protein 11 antibodies, and examine in detail the nature of the immune response in both the brain and the tumour samples for a better characterization of the immunopathogenesis of this condition. The presence of Kelch-like protein 11 antibodies was retrospectively assessed in patients referred to the French Reference Center for paraneoplastic neurological syndrome and autoimmune encephalitis with (i) antibody-negative paraneoplastic neurological syndrome [limbic encephalitis ( = 105), cerebellar degeneration ( = 33)] and (ii) antibody-positive paraneoplastic neurological syndrome [Ma2-Ab encephalitis ( = 34), antibodies targeting N-methyl-D-aspartate receptor encephalitis with teratoma ( = 49)]. Additionally, since 1 January 2020, patients were prospectively screened for Kelch-like protein 11 antibodies as new usual clinical practice.

View Article and Find Full Text PDF

Low-grade epilepsy-associated neuroepithelial tumours with a prominent oligodendroglioma-like component: The diagnostic challenges.

Neuropathol Appl Neurobiol

February 2022

AP-HM, CHU Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.

Aims: We searched for recurrent pathological features and molecular alterations in a retrospective series of 72 low-grade epilepsy-associated neuroepithelial tumours (LEATs) with a prominent oligodendroglioma-like component, in order to classify them according to the 2021 World Health Organization (WHO) classification of central nervous system (CNS) tumours.

Methods: Centralised pathological examination was performed as well as targeted molecular analysis of v-Raf murine sarcoma viral oncogene homologue B (BRAF) and fibroblast growth factor receptor 1 (FGFR1) by multiplexed digital polymerase chain reaction (mdPCR). DNA methylation profiling was performed in cases with sufficient DNA.

View Article and Find Full Text PDF

European network for oxysterol research (ENOR): 10 th anniversary.

J Steroid Biochem Mol Biol

November 2021

Laboratory of Vascular Biology and Mass Spectrometry, Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 04100, Latina, Italy. Electronic address:

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies show that brain tumors are more complicated than we thought, with different types and genetic differences that can't be seen just by looking at them under a microscope.
  • A specific group of these tumors, mainly found in kids, have a rare genetic change called PATZ1 fusions, which means they are more connected than previously believed.
  • Even though these tumors can often come back, they generally have a better outlook than typical aggressive tumors like glioblastoma, and researchers are looking into new treatment options based on their unique features.
View Article and Find Full Text PDF

The cIMPACT-NOW Update 7 has replaced the WHO nosology of "ependymoma, RELA fusion positive" by "Supratentorial-ependymoma, C11orf95-fusion positive". This modification reinforces the idea that supratentorial-ependymomas exhibiting fusion that implicates the C11orf95 (now called ZFTA) gene with or without the RELA gene, represent the same histomolecular entity. A hot off the press molecular study has identified distinct clusters of the DNA methylation class of ZFTA fusion-positive tumors.

View Article and Find Full Text PDF

The aim of this retrospective study was to assess the prognostic value of cytoplasmic versus nuclear RXRα expression in breast cancer (BC) tissue samples and to correlate the results with clinicopathological parameters. In 319 BC patients, the expression of RXRα was evaluated via immunohistochemistry. Prognosis-determining aspects were calculated through uni- and multivariate analyses.

View Article and Find Full Text PDF

FET:CREB fusions have been described in a variety of tumors from various phenotypes. Recently, these fusion transcripts were reported in intracranial tumors, variably named intracranial mesenchymal myxoid tumors or angiomatoid fibrous histiocytomas. Controversy remains concerning the terminology for these tumors.

View Article and Find Full Text PDF

Epstein-Barr virus (EBV) is a ubiquitous virus detected in up to 95% of the general population. Most people are asymptomatic, while some may develop a wide range of EBV-associated lymphoproliferative disorders (LPD). Among them, EBV-positive T/NK LPD are uncommon diseases defined by the proliferation of T- or NK-cells infected by EBV.

View Article and Find Full Text PDF